Peter Greenleaf, Aurinia Pharmaceuticals CEO
February 15, 2024 07:34 AM ESTUpdated 10:25 AM
People
R&D

Au­rinia fails to find buy­er, will shed pipeline to fo­cus on Lup­ky­nis

Kyle LaHucik

Senior Reporter

Au­rinia Phar­ma­ceu­ti­cals said it was un­able to at­tract any for­mal of­fers dur­ing its strate­gic re­view process, which be­gan last sum­mer af­ter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times